Using Circulating Tumor DNA in Colorectal Cancer
July 28, 2022
Our Director for Liquid Biopsy Research, Pashtoon Kasi, M.D., recently published an article, “Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices,” in the Journal of Clinical Oncology that is attracting a lot of attention.
The paper’s abstract is listed below, and you can find the full article by following this link.
EIPM's 2Q External Newsletter
July 14, 2022
Summer 2022
Dear Friend of the Englander Institute for Precision Medicine,
Welcome to our second quarterly newsletter of 2022!
A Conversation with Grace Le
July 11, 2022
We are pleased to introduce Grace Le, a student at Cornell Tech who spent several months at the beginning of the year working with our colleague Alex Sigaras, M.S., Assistant Professor of Research in Physiology and Biophysics, and director of the EIPM AI-XR Lab. We hope you enjoy learning more about her background and research interests.
Please tell our readers a little bit about yourself.
Mantle Cell Lymphoma Treatment Varies According to Setting
July 5, 2022
There is considerable variation in the management of mantle cell lymphoma across different clinical settings, and some strategies do not always conform with what might be expected, according to an analysis by investigators from Weill Cornell Medicine and other leading health institutions.
New Technology Helps Reveal Inner Workings of Human Genome
June 23, 2022
Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds. The genome is the complete set of genetic instructions, DNA or RNA, enabling an organism to function.
June 2022 EIPM Director's Memo
June 6, 2022
Dear Members of the Englander Institute,
I really enjoy talking to people about the exciting work happening at the EIPM, it can lead to all kinds of collaborations, professional opportunities, and new sources of support.
Immune Therapy Targets Cells that Cause Relapse
June 3, 2022
Genetically engineered immune cells successfully target the specific cancer cells that may be responsible for relapse of acute myeloid leukemia (AML), a type of blood cancer, and proved effective in animal models of the disease, according to a preclinical study by investigators at Weill Cornell Medicine. The new cell therapy, now being tested in phase 1 clinical trials, may ultimately help patients with AML to remain cancer-free.
New Cancer Subtype May Illuminate Treatment Strategy
May 27, 2022
Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.
New video: Reinventing Medicine at the EIPM!
May 10, 2022
We hope you enjoy watching our new video and taking a tour of our facilities and laboratories and learning more about how we’re reinventing medicine, with our Director Olivier Elemento, Ph.D. Dr. Laura Martin, Hiranmayi Ravichandran, Ilkay Us, and Alexandros Sigaras, M.S.